Uterus +Cervix+ 1 Falopian tube+1 Overy Biopsy - XL

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Histology of reproductive organs.

₹888₹1,269

30% OFF

Uterus + Cervix + 1 Fallopian Tube + 1 Ovary Biopsy - XL

Why is it done?
- Diagnoses malignancies: Detects and confirms cancer of the uterus, cervix, ovaries, and fallopian tubes, including endometrial cancer, cervical cancer, ovarian cancer, and tubal carcinoma
- Evaluates abnormal findings: Assesses abnormal pap smear results, abnormal vaginal bleeding, pelvic masses, and suspicious imaging findings on ultrasound or CT
- Assesses benign conditions: Identifies fibroids, polyps, endometrial hyperplasia, adenomyosis, and inflammatory conditions
- Stages malignancy: Provides tissue diagnosis and histological grading to determine treatment options and prognosis in cancer cases
- Monitors high-risk patients: Performs surveillance biopsies in patients with known malignancy or predisposing conditions requiring tissue evaluation
- Timing: Typically performed after abnormal imaging, imaging findings suspicious for malignancy, or when clinical examination suggests pathology requiring tissue diagnosis
Normal Range
- Normal/Negative Result: Benign tissue without malignancy; normal histological architecture; absence of dysplasia, hyperplasia, or neoplastic changes; normal endometrial tissue appropriate for cycle phase; normal cervical epithelium without dysplasia
- Interpretation Units: Histopathological diagnosis (tissue classification); results reported descriptively and categorically rather than numerical values
- Benign Findings: Fibroids (leiomyomas), polyps, cysts, inflammatory changes, endometritis, cervicitis, normal ovarian tissue
- Abnormal Findings: Malignant cells present; dysplasia (low-grade or high-grade); hyperplasia; carcinoma in situ; invasive cancer; grade 1, 2, or 3 adenocarcinoma; squamous cell carcinoma; or other malignant neoplasms
Interpretation
- Normal/Benign Histology: No evidence of malignancy; tissue demonstrates normal cellular architecture and appropriate differentiation; benign pathology such as fibroids or polyps may be documented; requires no urgent intervention but may require management depending on specific findings
- Dysplasia (CIN/Endometrial): Low-grade dysplasia (CIN1/LSIL): Mild cellular abnormalities; frequent regression but requires follow-up; increased risk of progression; High-grade dysplasia (CIN2-3/HSIL): Moderate to severe abnormalities; high risk of malignant transformation; requires immediate intervention such as excisional procedures or hysterectomy
- Carcinoma In Situ: Full-thickness dysplasia confined to epithelium without invasion; very high risk of invasive cancer; requires aggressive treatment including excision with margins or hysterectomy
- Invasive Carcinoma: Malignant cells infiltrating through epithelial basement membrane into underlying stroma; requires pathological staging (grade and stage); determines treatment approach including surgery, chemotherapy, and/or radiation; prognosis varies by histological type and grade
- Histological Grading: Grade 1 (Well-differentiated): Most favorable prognosis; Grade 2 (Moderately differentiated): Intermediate prognosis; Grade 3 (Poorly differentiated): Least favorable prognosis; higher grade indicates increased aggressiveness and poorer outcomes
- Factors Affecting Results: Specimen adequacy; tissue processing and fixation quality; immunohistochemical staining interpretations; molecular testing results; tumor heterogeneity; prior radiation or chemotherapy effects; infection or inflammation; menstrual cycle phase for endometrial samples
Associated Organs
- Primary Organs Involved: Uterus (endometrium and myometrium); Cervix (cervical epithelium); Fallopian tube (tubal epithelium); Ovary (ovarian tissue)
- Malignancies Diagnosed: Endometrial adenocarcinoma (Type I and II); Cervical squamous cell carcinoma and adenocarcinoma; Uterine sarcomas (carcinosarcoma, leiomyosarcoma); Ovarian epithelial cancers (serous, mucinous, endometrioid, clear cell); Primary fallopian tube carcinoma; Metastatic cancers to reproductive organs
- Benign Conditions Detected: Uterine fibroids (leiomyomas); Endometrial polyps; Endometrial hyperplasia; Adenomyosis; Chronic endometritis; Cervical polyps; Functional ovarian cysts; Tubal adhesions
- HPV-Related Conditions: HPV infection documentation; CIN (Cervical Intraepithelial Neoplasia) staging; cervical cancer progression; allows reflex HPV testing and viral load determination
- Potential Complications: Perforation of uterus during biopsy; infection/endometritis; hemorrhage or excessive bleeding; pregnancy loss if performed during pregnancy; pelvic inflammatory disease; adhesion formation; rare: death from complications
- Associated Risk Factors: Age, obesity, diabetes, hypertension, estrogen exposure, nulliparity, early menarche, late menopause, smoking, HPV infection, hereditary cancer syndromes (Lynch syndrome, BRCA mutations)
Follow-up Tests
- If Malignancy Confirmed: Staging imaging (CT chest/abdomen/pelvis, MRI, PET-CT); tumor markers (CEA, CA-125, HPV DNA); molecular testing (microsatellite instability, mismatch repair deficiency, KRAS/TP53 mutations); lymph node assessment; consultation with medical/radiation oncology
- If High-Grade Dysplasia Detected: Loop electrosurgical excision procedure (LEEP) or cold knife conization; colposcopy with directed biopsy; HPV testing; repeat cytology at 12 months; considerations for hysterectomy depending on age and reproductive plans
- If Low-Grade Dysplasia Detected: HPV testing; repeat cytology at 12 months; colposcopy if HPV positive; conservative management with close surveillance; repeat biopsy if findings persist or worsen
- Immunohistochemical Testing: ER/PR status (hormone receptor); HER2 testing; p53 and Ki-67 staining; mismatch repair protein stains (MLH1, MSH2, MSH6, PMS2); PD-L1 testing for immunotherapy eligibility
- Genetic/Molecular Testing: BRCA1/BRCA2 mutations (if ovarian cancer); Lynch syndrome testing (MLH1, MSH2, MSH6, PMS2, EPCAM); comprehensive genomic profiling; viral HPV subtyping (if cervical cancer)
- Surveillance Protocol: Regular follow-up pap smears (every 6-12 months for dysplasia); colposcopy with directed biopsy (every 6-12 months); imaging surveillance (ultrasound or CT every 3-6 months for cancer); tumor marker monitoring; annual clinical examination
- Related Complementary Tests: Pap smear/liquid-based cytology; transvaginal ultrasound; MRI pelvis; CA-125 serum testing; endometrial thickness measurement; infectious disease panel (STI screening if indicated)
Fasting Required?
- Fasting Requirement: No - Fasting is not required for this biopsy procedure
- Patient Preparation: Normal diet and hydration are permissible; take regular medications as prescribed unless otherwise instructed; avoid douching for 24-48 hours before procedure; avoid intercourse for 24-48 hours before procedure; empty bladder before procedure; wear comfortable clothing; arrange for transportation if anesthesia will be used
- Medications to Avoid: Aspirin and NSAIDs (ibuprofen, naproxen) - discontinue 3-5 days before; Anticoagulants (warfarin, apixaban, rivaroxaban) - consult physician regarding timing; Antiplatelet agents - discuss with provider; Herbal supplements (ginkgo, ginger, garlic) - discontinue 3-5 days before
- Special Instructions: Schedule biopsy in follicular phase (after menstruation, before ovulation) if possible; obtain informed consent documenting risks and benefits; review allergy history (latex, iodine, medications); establish IV access if general anesthesia planned; have emergency equipment available; NPO (nil per os) 6-8 hours if general anesthesia required; local anesthesia only does not require fasting
- Post-Procedure Care: Resume normal diet after procedure; mild cramping and spotting expected; use ibuprofen for pain relief as directed; avoid intercourse and douching for 1-2 weeks; avoid heavy lifting and strenuous exercise for 3-5 days; monitor for signs of infection (fever >101°F, severe pain, excessive bleeding) and seek immediate medical attention if occurs; follow-up appointment to review results with pathology

How our test process works!